Clinical trials: Drug
Hematologic Malignancies
A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies
This is an open-label, safety study of a single ProHema-CB product administered following myeloablative conditioning regimen in pediatric subjects with hematologic malignancies.
- Trial name
- NCT02354417
- Testing
- Biological: ProHema-CB
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Fate Therapeutics
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT04776018
- Testing
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Where
- 13 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Takeda
Geriatric Assessment, Frail Elderly
Drug Reduction in Older Patients: The DROP Trial
Project Objectives: The proposed randomized, controlled trial will evaluate the effects of procedures to reduce medications among hospitalized older Veterans discharged to nursing homes using an hybrid study design to inform…
- Conditions
- Geriatric Assessment, Frail Elderly, Skilled Nursing Facilities, Patient-centered Care
- Trial name
- DROP (NCT03722017)
- Testing
- Deprescribing intervention
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- VA Office of Research and Development
Peripheral Arterial Disease
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- DALIA (NCT01026389)
- Testing
- Dotarem, Gadovist
- Where
- Austria
- Volunteers
- 189 people
- Sponsor
- Guerbet
Gastroesophageal Reflux
Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.
- Trial name
- NCT00847210
- Testing
- Dexlansoprazole MR
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Healthy
Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers
The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state
- Trial name
- NCT01679613
- Testing
- Nintedanib, Ketoconazole
- Where
- Germany
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Epilepsy
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02565108
- Testing
- GWP42003-P 20 mg/kg/Day Dose, Clobazam
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Jazz Pharmaceuticals
HepatoCellular Carcinoma
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term…
- Trial name
- NCT03007225
- Testing
- Trans-arterial chemoembolization (TACE), TACE with Drug Eluting Beads procedure
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Meloxicam vs Placebo for Mobilization
This research study is evaluating a drug called meloxicam to see if it provides a benefit to people receiving Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
- Trial name
- NCT02003625
- Testing
- GCSF, meloxicam
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Massachusetts General Hospital
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Prostate Cancer
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
- Trial name
- NCT02142608
- Testing
- BR55
- Where
- 2 sites in United States, France
- Volunteers
- 19 people
- Sponsor
- Bracco Diagnostics, Inc
COVID-19
Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
The aim of this multi-part Phase 1 study is to evaluate the drug-drug interaction (DDI) potential of ALG-097558 via co-administration with a P-gp substrate (dabigatran) and a CYP3A4 inhibitor/P-gp inhibitor (itraconazole).
- Trial name
- NCT06945276
- Testing
- ALG-097558, Dabigatran, Itraconazole
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Opioid Dependence
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
To conduct a randomized clinical trial (RCT) of a community-friendly behavioral intervention designed to reduce HIV risk behavior among injection drug users (IDUs) in drug treatment by comparing risk-behavior outcomes of four…
- Trial name
- NCT01741350
- Testing
- Community-friendly Health Recovery Program, Time-and-Attention-Matched Control Condition
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- University of Connecticut
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT01306643
- Testing
- Idelalisib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma
- Trial name
- NCT02893917
- Testing
- Cediranib, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Depression, Anxiety
Potency and Precision Investigation
The overarching goal of this study is to establish initial proof of mechanism for precision interventions in an adult population.
- Trial name
- PAPI (NCT06240091)
- Testing
- DISC-MA
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Woebot Health
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.